Why the Universal Biosensors (ASX:UBI) share price is up 5% today

The Universal Biosensors, Inc. (ASX: UBI) share price has lifted today. This comes after the company announced that it has signed a new deal with LifeScan.

| More on:
hand on touch screen lit up by a share price chart moving higher

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Universal Biosensors, Inc. (ASX: UBI) share price is on the rise today after the company announced that it has signed a new deal with LifeScan.

During mid-morning trade, shares in the medical diagnostics company reached an intraday high of 46 cents. However, the Universal share price has since retreated to 41 cents, up 5.1%.

Quick take on Universal

Universal is a specialist medical diagnostics company that focuses on the research, development, manufacture and commercialisation of diagnostic devices. Used by both consumers and professionals, these test systems can be adopted in an array of point-of-care (POC) settings.

According to Universal, the POC diagnostic market is worth US$15 billion a year.

What's driving the Universal share price higher?

According to its release, Universal advised that it entered in an exclusive licencing agreement with LifeScan Global Corporation. The agreement will see both parties work together to develop a device that is able to detect and monitor diabetes in animals.

Using LifeScan's technology, Universal aims to manufacture and sell a discrete single point measurement to monitor glucose. The device will include a biosensor, test strip and a meter for diabetes management.

Under the terms, standard customary conditions apply to both Universal and LifeScan. However, once the product is launched, if annual sales drop below US$10 million, the term of the contract will end.

Previously, LifeScan worked with Universal in commercialising and developing a diabetes strip and meter. To date, the company has sold more than 10 billion diabetes strips worldwide.

CEO commentary

Universal CEO Mr John Sharman spoke of the partnership, saying:

LifeScan paid UBI A$44.6 million in 2019 to buy out UBI's royalty stream which was based on the diabetes products developed using UBI technology. Our new deal with LifeScan means that we can use our existing know-how and combine it with the LifeScan technology to develop a new diabetes product for animals, which we will own.

Most if not all of the technology, know-how and manufacturing capability for diabetes strips and meters already exists at UBI and we expect to have a product available for sale within 18 – 24 months. Our ambition is to win a significant share of the animal diabetes market.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Woman with a scared look has hands on her face.
Broker Notes

Bapcor shares fell more than 30% yesterday. Should investors buy in the dip?

Is this a value opportunity?

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Broker Notes

Broker raises price targets on 2 ASX 200 shares to buy

Ord Minnett has just upped its 12-month share price targets on 2 buy-rated ASX 200 stocks.

Read more »

Man with rocket wings which have flames coming out of them.
Share Gainers

Guess which ASX All Ords stock just rocketed 34% on strong earnings growth

Investors just sent this ASX All Ords stock surging 34%. Here’s what’s happening.

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why DroneShield, Gentrack, Metals X, and Northern Star shares are tumbling today

These shares are ending the week in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Dimerix, Newmont, Regal Partners, and Titomic shares are storming higher

These shares are having a good finish to the week. Let's see why.

Read more »

Man drawing an upward line on a bar graph symbolising a rising share price.
Broker Notes

Morgans says these ASX can rise 30% to 50%

The broker has good things to say about these shares.

Read more »

Two businessmen look out at the city from the top of a tall building.
Broker Notes

2 ASX REITs to buy in July: expert

Is it time to consider ASX REITs?

Read more »